<DOC>
	<DOCNO>NCT02244099</DOCNO>
	<brief_summary>The purpose study characterize improve control substance , carisoprodol tramadol use internal medicine resident ' clinic . Specific objective study include : - To measure adherence control substance treatment agreement ( CSTA ) implementation population management intervention - To determine number patient CSTA discrepancy identify urine drug screen Ohio Automated Rx Reporting System ( OARRS ) report - To track number patient morphine equivalent dose ( MED ) ≥ 80 mg/day implementation review intervention - To characterize healthcare utilization patient take controlled substance , carisoprodol , tramadol track mean number ED visit , hospital admission , telephone call , clinic office visit 6 month period</brief_summary>
	<brief_title>Controlled Substance Treatment Agreements Internal Medicine Residents ' Clinic</brief_title>
	<detailed_description>Reporting workbench use generate report EMR patient consent physician prescribe controlled substance , carisoprodol , tramadol least 3 time past 6 month . This report also include demographic , number ED visit last 6 month , hospital admission last 6 month , number telephone call document last 6 month , number clinic visit last 6 month , number miss clinic visit last 6 month , control substance prescribed , direction use , number tabs medication prescribe , number refill give , order date date completion urine drug screen last 6 month , chronic pain list medical problem , control substance treatment agreement sign scan EMR . For patient consenting physician , EMR review track next clinic visit date , urine toxicology screen result , documentation Ohio Automated Rx Reporting System ( OARRS ) review . The MED patient obtain OARRS report include data collection form . For patient take opioid substance MED ≥ 80 mg/day review appropriateness medication dose base EMR documentation conduct clinic physician and/or pharmacist . This do order make recommendation resident physician base best practice recommend control substance agreement . For patient consent physician upcoming office visit schedule , recommendation improve adherence CSTA change control substance , carisoprodol , tramadol prescribe base EMR review finding give patient 's physician prior office visit . Because intervention quality improvement intervention study physician decision make direct interaction patient , patient know study occur . An EMR review patient 's visit complete track acceptance recommendation lead change parameter list data analysis section . Additionally , second report generate report workbence 6 month implementation workflow include patient consent physician prescribe controlled substance , tramadol , carisoprodol ( include initial report new patient control substance since time report generate ) characterize improvement parameter patient clinic whole track improvement adherence control substance treatment agreement . See study procedure Figure 1 . Data Collection start 8/1/14 continue 12/31/15 .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Carisoprodol</mesh_term>
	<criteria>Age 18 year old Residents attend physician work resident continuity practice Age &lt; 18 year age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Controlled substance prescribing</keyword>
	<keyword>Controlled substance treatment agreement</keyword>
	<keyword>Opioid use</keyword>
</DOC>